To assess more direct effects of ROCK1/2 inhibition, we performed an EMT-directed qPCR array in A375M2 and WM1361 melanoma cells (BRAFV600E or NRASQ61L-driven melanoma, respectively, to account for the main melanoma oncogenic drivers) treated with ROCKi for only 4 h. This evidence concerns the gene ROCK1 and melanoma.